LYMPHOMAS

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.

Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.

Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.

CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.

Phase 2 data show atezolizumab delivers durable responses in relapsed/refractory NK/T-cell lymphoma, with PD‑L1 markers helping predict benefit.

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

Explore how REMS removal streamlines CAR T-cell access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

FDA grants designations to off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Phase 1/2 SIDNEY interim results show EO2463 boosts CD8 T cells, linking to longer PFS and responses in watch-and-wait patients with indolent NHL.

Ten-year RELEVANCE results show chemo-free R2 matches immunochemotherapy for advanced follicular lymphoma, with comparable survival and safety.

Early trial shows off-the-shelf immunotherapy combo boosts responses in relapsed B-cell lymphoma with manageable CRS and safety.

Survey reveals race and sex gaps in lymphoma trial barriers—travel, costs, complexity, and mistrust—pointing to navigators, decentralized visits, and reimbursement fixes.

Phase 3 MANGROVE shows chemo-free zanubrutinib plus rituximab extends PFS in untreated mantle cell lymphoma, with no new safety issues.

Phase 3 trial shows chemo-free epcoritamab plus lenalidomide cuts progression risk in relapsed DLBCL, with no new safety signals.